Lilly disses Amgen and Mirati as it debuts new KRAS molecule
Eli Lilly is rejoining the KRAS hunt.
The Indianapolis Big Pharma revealed Thursday, in an abstract for AACR, that it has been working on a new small molecule to target the infamous oncogene and are planning to put it into Phase I later this year. It marks Lilly’s first public foray into the field in nearly a year, since it ditched its first molecule after seeing dangerous side effects in five patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.